Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 19/20 | 0.74 |
| ▸ | GNA15 | P30679 | 1/20 | 0.47 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3745518 | 1.00 | FFAR1 (0.74) | FFAR1GNA15PTGER3FFAR4TDP1 | |
| SCHEMBL13043546 | 0.94 | FFAR1 (0.82) | FFAR1GNA15PTGER3FFAR4TDP1 | |
| SCHEMBL3753745 | 0.94 | FFAR1 (0.82) | FFAR1GNA15PTGER3FFAR4TDP1 | |
| SCHEMBL3753742 | 0.94 | FFAR1 (0.82) | FFAR1GNA15PTGER3FFAR4TDP1 | |
| Trifluoroacetic Acid SCHEMBL3742317 | 0.90 | FFAR1 (0.72) | FFAR1GNA15PTGER3FFAR4TDP1 | |
| Trifluoroacetic Acid SCHEMBL3742319 | 0.90 | FFAR1 (0.72) | FFAR1GNA15PTGER3FFAR4TDP1 | |
| Trifluoroacetic Acid SCHEMBL3741399 | 0.87 | FFAR1 (0.77) | FFAR1GNA15PTGER3FFAR4TDP1 | |
| Trifluoroacetic Acid SCHEMBL3741401 | 0.87 | FFAR1 (0.77) | FFAR1GNA15PTGER3FFAR4TDP1 | |
| SCHEMBL13043494 | 0.87 | FFAR1 (0.86) | FFAR1GNA15PTGER3FFAR4TDP1 | |
| SCHEMBL3734073 | 0.85 | FFAR1 (1.00) | FFAR1GNA15PTGER3FFAR4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834013-B2 | Racemic-(trans)-2-[4-({[3-(phenyloxy)phenyl]methyl}ammonium)phenyl]cyclopropanecarboxylic acid; type II diabetes; G protein-coupled receptor 40 (GPR40) agonists | GLAXOSMITHKLINE LLC (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090105257-A1 | AMINOPHENYLCYCLOPROPYL CARBOXYLIC ACIDS AND DERIVATIVES AS AGONISTS TO GPR40 | GLAXOSMITHKLINE LLC | 2009-04-23 | — | — | US | disclosed |
| WO-2005051890-A1 | AMINOPHENYLCYCLOPROPYL CARBOXYLIC ACIDS AND DERIVATIVES AS AGONISTS TO GPR40 | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105257-A1 | AMINOPHENYLCYCLOPROPYL CARBOXYLIC ACIDS AND DERIVATIVES AS AGONISTS TO GPR40 | GPR65, GPR88, GPR84 | FFAR1 23/4885GNA15 891/4885PTGER3 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.